Services
Biomarkers that show response or non-response to a particular drug are at the heart of the personalised medicine movement. They are also becoming requirements in clinical trials for better patient stratification and improved outcomes. For a company developing a therapy, having a biomarker strategy is a necessity.
At CellCarta, we offer industry-leading biomarker services, specialising in biomarker assay development and validation for pharmaceutical and biotech. Our expertise covers biomarker discovery services and clinical biomarker testing services.
We see ourselves as a partner of choice for your biomarker strategies, offering a wide range of biomarker assay services including immune and cell-based assays.
Our biomarker assay development and validation approach combines state-of-the-art bioanalytical laboratory techniques to deliver biomarker strategies tailored to your research needs. Whether you need biomarker quantification and validation for exploratory endpoints or regulatory approval, our validated platforms provide robust, high quality data to inform your decisions.
Our scientists have years of experience in developing mass spectrometry (MS) workflows, customising immunoassays and designing flow cytometry panels for specific clinical needs. We also offer a full range of histopathology and molecular pathology services to clinical standards.
Our biomarker analysis services include multiparametric flow cytometry, allowing sensitive and precise cell enumeration of various populations such as TBNK. Another key pharmacodynamic (PD) biomarker includes myeloid-derived suppressor cells (MDSC) used in the field of immunotherapies to monitor treatment response.
Learn more about our Flow Cytometry platform
These assays provide quantitative measurement of cellular immune related activities, key in biomarker development and validation. Our validated FluoroSpot and ELISpot assays track therapeutic immune modulation.
Our team has extensive experience in customizing and validating these assays to specific cytokines, including IFNγ and IL-4.
Learn more about our ELISpot/FluoroSpot services
Immunoassays detect analytes such as proteins, hormones and antibodies with high specificity even at low concentrations.
Monitoring changes in patterns of analytes with immunoassays can lead to the discovery of new biomarkers. Once identified, these can be further quantified using MSD®, OlinkTM, or ELLA specific panels.
With the advantage of being high throughput, multiplexed, and often requiring only a small volume of sample, immunoassays with valuable clinical samples can be performed with ease.
Learn more about our Immunoassays
Identification and monitoring of biomarkers is also feasible using high-content cytometric analysis obtained from mass cytometry assays.
This platform provides high-content cytometric analysis up to 40 markers, that can confidently be used to investigate clinical samples.
We are leading the way in mass cytometry by providing services in a GCLP environment. Our team also offers assistance in data interpretation with advanced visualizations generated with our in-house software CellEngine.
Learn more about our Mass Cytometry CyTOF platform
Biomarker discovery and monitoring from tissue samples following treatment is at the core of what our board-certified pathologists do. Patient stratification biomarkers such as ALK, EGFR, HER2, and BRAF are commonly used as companion diagnostic assays, and at CellCarta, we harness the power of multiplex immunohistochemistry (mIHC), to monitor these biomarkers under regulatory standards.
With expertise in multiple staining platforms, our team can also support biomarker discovery research in tissue samples.
Learn more about our Histopathology services
DNA mutations, RNA fusions, DNA methylation patterns, and microsatellite instabilities may all represent clinically relevant biomarkers.
Our team has the expertise to properly extract DNA and RNA from clinical samples and perform standardized molecular analysis using the latest bioanalytical testing technologies.
Learn more about our Genomic services
Our expertise with mass spectrometry (MS) focuses on absolute quantification of biomarkers.
The Multiple Reaction Monitoring (MRM) approach is both fit for clinical applications and regulatory submission. In collaboration with various partners, we brought numerous biomarkers to the markets, as development tools and clinical diagnostic tests.
Our off-the-shelf panels can be customized to measure clinically relevant biomarkers in FFPE samples.
Highly quantitative assays measuring the expression of validated targets in other sample types, including soluble B-cell maturation antigen (BCMA) in plasma, are also readily available.
Learn more about our Mass Spectrometry-based Biomarker Services
Work with CellCarta for innovative biomarker development and strategy solutions to boost your pipeline. Find out how our biomarker-assay expertise can help you achieve your research goals.
Contact us today for customized biomarker solutions.